Cancer News and Research

Latest Cancer News and Research

Protein complex proves valuable for changing cell fate

The DNA contained within each of our cells is exactly the same, yet different types of cells - skin cells, heart cells, brain cells - perform very different functions. The ultimate fate of these cells is encoded not just in the DNA, but in a specific pattern of chemical modifications that overlay the DNA structure.

7 Jan 2010

Balanced diet and exercise are the only reliable ways to lose weight

It's time to set the record straight. The only reliable way to lose weight is to eat less or exercise more. Preferably both.

7 Jan 2010

Survivors of pediatric cancer at greater risk for cardiovascular disease

Survivors of pediatric cancer are at greater risk for high cholesterol, diabetes and high blood pressure, all of which predispose them to heart disease. These risk factors for heart disease are being found at an earlier age than in the general population, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

7 Jan 2010

CCAC doubles its efforts to convince Canadians to prevent colorectal cancer

Following the results of the Angus Reid Strategies and the Applied Health Research Centre at Toronto's St. Michael's Hospital survey conducted on behalf of the Canadian Partnership Against Cancer finding that the majority of Canadians have a good understanding of the benefits of colorectal cancer screening, but are not taking action to get screened, the Colorectal Cancer Association of Canada ("CCAC") is doubling its efforts in 2010 to convince Canadians that they must be more proactive concerning their health and the onset of colorectal cancer.

7 Jan 2010

Data highlights importance of follow-up exams for patients with history of advanced adenomas

A new study examines the occurrence of interval colorectal cancer despite regular colonoscopy and highlights the importance of close follow-up for patients who have a history of advanced adenomas, which are precancerous polyps.

7 Jan 2010

Phase II clinical trial results of Liposome-Entrapped Paclitaxel announced

NeoPharm, Inc. today announced the results of a Phase II clinical trial of Liposome-Entrapped Paclitaxel (LEP) an active component of Taxol®. This multicenter, open-label trial of LEP was conducted at 5 centers in India.

7 Jan 2010

Response Genetics and Genetic Technologies sign exclusive distribution and services agreement

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, and Genetic Technologies Ltd. (ASX: GTG; NASDAQ: GENE), the leading private genetic testing laboratory in Australia, today announced an exclusive distribution and services agreement.

7 Jan 2010

SDI to discover biomarkers in collaboration with Fred Hutchinson Cancer Research Center

SDI (Strategic Diagnostics Inc.), a provider of biotechnology-based products and services, and Fred Hutchinson Cancer Research Center (the Hutchinson Center) today jointly announced they will collaborate to discover biomarkers for use in the early detection of a variety of cancers.

7 Jan 2010

Senate: Democratic retirements raise questions about political support for health reform

The retirement announcements from Sen. Byron Dorgan (D-N.D.) and Sen. Chris Dodd (D-Conn.) [are] unlikely have a direct impact on the final push for health care legislation, Democratic and health care insiders said Wednesday.

7 Jan 2010

Study explains how H. pylori infection causes stomach cancer

Researchers report that Helicobacter pylori, the only bacterium known to survive in the harsh environment of the human stomach, directly activates an enzyme in host cells that has been associated with several types of cancer, including gastric cancer.

7 Jan 2010

MabCure signs clinical research agreement to diagnose ovarian cancer

MabCure, N.V. (“MabCure”) a wholly-owned subsidiary of MabCure Inc., a biotech company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has signed a clinical research agreement with the Ramathibodi Hospital, Mahidol University in Bangkok, Thailand.

7 Jan 2010

Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38

Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection).

6 Jan 2010

Dana-Farber researcher honored for scientific advancement

Kai W. Wucherpfennig, MD, PhD, a researcher at Dana-Farber Cancer Institute, has been named a Fellow for the American Association for the Advancement of Science (AAAS).

6 Jan 2010

New evidence suggests long-term exposure to cell phone signals may protect against Alzheimer's disease

The millions of people who spend hours every day on a cell phone may have a new excuse for yakking. A surprising new study in mice provides the first evidence that long-term exposure to electromagnetic waves associated with cell phone use may actually protect against, and even reverse, Alzheimer's disease.

6 Jan 2010

Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206

CytRx Corporation, a biopharmaceutical company, today announced that the Tumor Biology Center, Freiburg, Germany, plans to initiate a Phase 2 clinical trial with CytRx’s doxorubicin prodrug INNO-206 as a treatment for patients with advanced pancreatic cancer.

6 Jan 2010

New study reveals high-silica coal causes lung cancer

The volcanic eruptions thought responsible for Earth's largest mass extinction - which killed more than 70 percent of plants and animals 250 million years ago - is still taking lives today. That's the conclusion of a new study showing, for the first time, that the high silica content of coal in one region of China may be interacting with volatile substances in the coal to cause unusually high rates of lung cancer.

6 Jan 2010

Mayo Clinic research ends major controversy in cancer research

ChromoCure, Inc. (PINKSHEETS: KKUR) is pleased to announce the basis for the Company's technology confirmed by recent Mayo Clinic researchers. Their findings, which appear in the current issue of the journal Cancer Cell, along with an independent commentary on the discovery, end a major controversy in the field of cancer research as to whether aneuploidy is a cause or a consequence of cancer and further proves the aneuploidy basis of cancer.

6 Jan 2010